Cervarix: Not the New
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Mmrv Vaccine
VACCINE INFORMATION STATEMENT (Measles, Mumps, Many Vaccine Information Statements are available in Spanish and other languages. MMRV Vaccine Rubella and See www.immunize.org/vis Varicella) Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis These are recommended ages. But children can get the Measles, Mumps, Rubella and second dose up through 12 years as long as it is at least 1 Varicella 3 months after the first dose. Measles, Mumps, Rubella, and Varicella (chickenpox) can be serious diseases: Children may also get these vaccines as 2 separate shots: MMR (measles, mumps and rubella) and Measles varicella vaccines. • Causes rash, cough, runny nose, eye irritation, fever. • Can lead to ear infection, pneumonia, seizures, brain 1 Shot (MMRV) or 2 Shots (MMR & Varicella)? damage, and death. • Both options give the same protection. Mumps • One less shot with MMRV. • Causes fever, headache, swollen glands. • Children who got the first dose as MMRV have • Can lead to deafness, meningitis (infection of the brain had more fevers and fever-related seizures (about and spinal cord covering), infection of the pancreas, 1 in 1,250) than children who got the first dose as painful swelling of the testicles or ovaries, and, rarely, separate shots of MMR and varicella vaccines on death. the same day (about 1 in 2,500). Rubella (German Measles) Your doctor can give you more information, • Causes rash and mild fever; and can cause arthritis, including the Vaccine Information Statements for (mostly in women). MMR and Varicella vaccines. -
Theos Turbulentpriests Reform:Layout 1
Turbulent Priests? The Archbishop of Canterbury in contemporary English politics Daniel Gover Theos Friends’ Programme Theos is a public theology think tank which seeks to influence public opinion about the role of faith and belief in society. We were launched in November 2006 with the support of the Archbishop of Canterbury, Dr Rowan Williams, and the Cardinal Archbishop of Westminster, Cardinal Cormac Murphy-O'Connor. We provide • high-quality research, reports and publications; • an events programme; • news, information and analysis to media companies and other opinion formers. We can only do this with your help! Theos Friends receive complimentary copies of all Theos publications, invitations to selected events and monthly email bulletins. If you would like to become a Friend, please detach or photocopy the form below, and send it with a cheque to Theos for £60. Thank you. Yes, I would like to help change public opinion! I enclose a cheque for £60 made payable to Theos. Name Address Postcode Email Tel Data Protection Theos will use your personal data to inform you of its activities. If you prefer not to receive this information please tick here By completing you are consenting to receiving communications by telephone and email. Theos will not pass on your details to any third party. Please return this form to: Theos | 77 Great Peter Street | London | SW1P 2EZ S: 97711: D: 36701: Turbulent Priests? what Theos is Theos is a public theology think tank which exists to undertake research and provide commentary on social and political arrangements. We aim to impact opinion around issues of faith and belief in The Archbishop of Canterbury society. -
Vaccine Information for PARENTS and CAREGIVERS
NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES Division of the National Health Laboratory Service VACCINE INFOR MATION FOR PARENTS & CAREGIVERS First Edition November 2016 Editors-in-Chief Nkengafac Villyen Motaze (MD, MSc, PhD fellow), Melinda Suchard (MBBCh, FCPath (SA), MMed) Edited by: Cheryl Cohen, (MBBCh, FCPath (SA) Micro, DTM&H, MSc (Epi), Phd) Lee Baker, (Dip Pharm) Lucille Blumberg, (MBBCh, MMed (Micro) ID (SA) FFTM (RCPS, Glasgow) DTM&H DOH DCH) Published by: Ideas Wise and Wonderful (IWW) for National Institute for Communicable Diseases (NICD) First Edition: Copyright © 2016 Contributions by: Clement Adu-Gyamfi (BSc Hons, MSc), Jayendrie Thaver (BSc), Kerrigan McCarthy, (MBBCh, FCPath (SA), DTM&H, MPhil (Theol) Kirsten Redman (BSc Hons), Nishi Prabdial-Sing (PhD), Nonhlanhla Mbenenge (MBBCh, MMED) Philippa Hime (midwife), Vania Duxbury (BSc Hons), Wayne Howard (BSc Hons) Acknowledgments: Amayeza, Vaccine Information Centre (http://www.amayeza-info.co.za/) Centre for Communicable Diseases Fact Sheets (http://www.cdc.gov/vaccines/hcp/vis/) World Health Organization Fact Sheets (http://www.who.int/mediacentre/factsheets/en/) National Department of Health, South Africa (http://www.health.gov.za/) Disclaimer This book is intended as an educational tool only. Information may be subject to change as schedules or formulations are updated. Summarized and simplified information is presented in this booklet. For full prescribing information and contraindications for vaccinations, please consult individual package inserts. There has been -
Supplemental Information and Guidance for Vaccination Providers Regarding Use of 9-Valent HPV Vaccine
Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV A 9-valent human papillomavirus (HPV) vaccine (9vHPV, Gardasil 9, Merck & Co.) was licensed for use in females and males in December 2014.1,2,3,4 The 9vHPV was the third HPV vaccine licensed in the United States by the Food and Drug Administration (FDA); the other vaccines are bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline), licensed for use in females, and quadrivalent HPV vaccine (4vHPV, Gardasil, Merck & Co.), licensed for use in females and males.5 In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended 9vHPV as one of three HPV vaccines that can be used for routine vaccination of females and one of two HPV vaccines for routine vaccination of males.6 After the end of 2016, only 9vHPV will be distributed in the United States. In October 2016, ACIP updated HPV vaccination recommendations regarding dosing schedules.7 CDC now recommends two doses of HPV vaccine (0, 6–12 month schedule) for persons starting the vaccination series before the 15th birthday. Three doses of HPV vaccine (0, 1–2, 6 month schedule) continue to be recommended for persons starting the vaccination series on or after the 15th birthday and for persons with certain immunocompromising conditions. Guidance is needed for persons who started the series with 2vHPV or 4vHPV and may be completing the series with 9vHPV. The information below summarizes some of the recommendations included in ACIP Policy Notes and provides additional guidance.5-7 Information about the vaccines What are some of the similarities and differences between the three HPV vaccines? y Each of the three HPV vaccines is a noninfectious, virus-like particle (VLP) vaccine. -
AAMC Standardized Immunization Form
AAMC Standardized Immunization Form Middle Last Name: First Name: Initial: DOB: Street Address: Medical School: City: Cell Phone: State: Primary Email: ZIP Code: AAMC ID: MMR (Measles, Mumps, Rubella) – 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option. Copy Note: a 3rd dose of MMR vaccine may be advised during regional outbreaks of measles or mumps if original MMR vaccination was received in childhood. Attached Option1 Vaccine Date MMR Dose #1 MMR -2 doses of MMR vaccine MMR Dose #2 Option 2 Vaccine or Test Date Measles Vaccine Dose #1 Serology Results Measles Qualitative -2 doses of vaccine or Measles Vaccine Dose #2 Titer Results: Positive Negative positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Mumps Vaccine Dose #1 Serology Results Mumps Qualitative -2 doses of vaccine or Mumps Vaccine Dose #2 Titer Results: Positive Negative positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Serology Results Rubella Qualitative Positive Negative -1 dose of vaccine or Rubella Vaccine Titer Results: positive serology Quantitative Serologic Immunity (IgG antibody titer) Titer Results: _____ IU/ml Tetanus-diphtheria-pertussis – 1 dose of adult Tdap; if last Tdap is more than 10 years old, provide date of last Td or Tdap booster Tdap Vaccine (Adacel, Boostrix, etc) Td Vaccine or Tdap Vaccine booster (if more than 10 years since last Tdap) Varicella (Chicken Pox) - 2 doses of varicella vaccine or positive serology Varicella Vaccine #1 Serology Results Qualitative Varicella Vaccine #2 Titer Results: Positive Negative Serologic Immunity (IgG antibody titer) Quantitative Titer Results: _____ IU/ml Influenza Vaccine --1 dose annually each fall Date Flu Vaccine © 2020 AAMC. -
Carina Trimingham -V
Neutral Citation Number: [2012] EWHC 1296 (QB) Case No: HQ10D03060 IN THE HIGH COURT OF JUSTICE QUEEN'S BENCH DIVISION Royal Courts of Justice Strand, London, WC2A 2LL Date: 24/05/2012 Before: THE HONOURABLE MR JUSTICE TUGENDHAT - - - - - - - - - - - - - - - - - - - - - Between: Carina Trimingham Claimant - and - Associated Newspapers Limited Defendant - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Matthew Ryder QC & William Bennett (instructed by Mishcon de Reya) for the Claimant Antony White QC & Alexandra Marzec (instructed by Reynolds Porter Chamberlain LLP) for the Defendant Hearing dates: 23,24,25,26,27 April 2012 - - - - - - - - - - - - - - - - - - - - - Approved Judgment I direct that pursuant to CPR PD 39A para 6.1 no official shorthand note shall be taken of this Judgment and that copies of this version as handed down may be treated as authentic. ............................. THE HONOURABLE MR JUSTICE TUGENDHAT THE HONOURABLE MR JUSTICE TUGENDHAT Trimingham v. ANL Approved Judgment Mr Justice Tugendhat : 1. By claim form issued on 11 August 2010 the Claimant (“Ms Trimingham”) complained that the Defendant had wrongfully published private information concerning herself in eight articles. 2. Mr Christopher Huhne MP had been re-elected as the Member of Parliament for Eastleigh in Hampshire at the General Election held in May 2010, just over a month before the first of the articles complained of. He became Secretary of State for Energy in the Coalition Government. He was one of the leading figures in the Government and in the Liberal Democrat Party. In 2008 Ms Trimingham and Mr Huhne started an affair, unknown to both Mr Huhne’s wife, Ms Pryce, and Ms Trimingham’s civil partner. By 2008 Mr Huhne had become the Home Affairs spokesman for the Liberal Democrats. -
Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis
processes Article Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis Rafael G. Ferreira 1,* , Neal F. Gordon 2, Rick Stock 2 and Demetri Petrides 3 1 Intelligen Brasil, Sao Paulo 01227-200, Brazil 2 BDO USA, LLP, Boston, MA 02110, USA; [email protected] (N.F.G.); [email protected] (R.S.) 3 Intelligen, Inc., Scotch Plains, NJ 07076, USA; [email protected] * Correspondence: [email protected] Abstract: The COVID-19 pandemic has motivated the rapid development of numerous vaccines that have proven effective against SARS-CoV-2. Several of these successful vaccines are based on the adenoviral vector platform. The mass manufacturing of these vaccines poses great challenges, especially in the context of a pandemic where extremely large quantities must be produced quickly at an affordable cost. In this work, two baseline processes for the production of a COVID-19 adenoviral vector vaccine, B1 and P1, were designed, simulated and economically evaluated with the aid of the software SuperPro Designer. B1 used a batch cell culture viral production step, with a viral titer of 5 × 1010 viral particles (VP)/mL in both stainless-steel and disposable equipment. P1 used a perfusion cell culture viral production step, with a viral titer of 1 × 1012 VP/mL in exclusively disposable equipment. Both processes were sized to produce 400 M/yr vaccine doses. P1 led to a smaller cost per dose than B1 ($0.15 vs. $0.23) and required a much smaller capital investment ($126 M vs. $299 M). The media and facility-dependent expenses were found to be the main contributors to the operating cost. -
Bad News for Disabled People: How the Newspapers Are Reporting Disability
Strathclyde Centre for Disability Research and Glasgow Media Unit Bad News for Disabled People: How the newspapers are reporting disability In association with: Contents PAGE 1. Acknowledgements 2 2. Author details 3 3. Main findings 4 4. Summary 6 Part 2 5. Introduction 16 6. Methodology and Design 18 6.1 Content analysis 18 6.2 Audience reception analysis 20 7. Content analysis:Results 22 7.1 Political discussion and critiques of policy 22 7.2 Changes in the profile of disability coverage and ‘sympathetic’ portrayals 32 7.3 Changes in the profile of representations of the ‘undeserving’ disability claimant 38 8. Audience reception analysis 59 8.1 How is disability reported in the media 59 8.2 Views on disabled people 62 8.3 Views on benefits and benefit claimants 64 8.4 Views on government policy 67 9. Conclusion 69 10. References 73 Appendix 1. Coding schedule 80 Appendix 2. Detailed descriptors for coding and analysis 85 1 Acknowledgements This research was commissioned by Inclusion London and their financial sponsorship and administrative backing is gratefully recognised. In particular we would like to acknowledge the help and collaborative support of Anne Kane who provided us with very valuable and helpful advice throughout the research and had a significant input in the drafting of the final report. We would also like to thank the following researchers who worked in the Glasgow Media Group and who tirelessly, carefully and painstakingly undertook the content analysis of the media: Stevie Docherty, Louise Gaw, Daniela Latina, Colin Macpherson, Hannah Millar and Sarah Watson. We are grateful to Allan Sutherland and Jo Ferrie for their contributions to the data collection. -
2021-22 School Year New York State Immunization Requirements for School Entrance/Attendance1
2021-22 School Year New York State Immunization Requirements for School Entrance/Attendance1 NOTES: Children in a prekindergarten setting should be age-appropriately immunized. The number of doses depends on the schedule recommended by the Advisory Committee on Immunization Practices (ACIP). Intervals between doses of vaccine should be in accordance with the ACIP-recommended immunization schedule for persons 0 through 18 years of age. Doses received before the minimum age or intervals are not valid and do not count toward the number of doses listed below. See footnotes for specific information foreach vaccine. Children who are enrolling in grade-less classes should meet the immunization requirements of the grades for which they are age equivalent. Dose requirements MUST be read with the footnotes of this schedule Prekindergarten Kindergarten and Grades Grades Grade Vaccines (Day Care, 1, 2, 3, 4 and 5 6, 7, 8, 9, 10 12 Head Start, and 11 Nursery or Pre-k) Diphtheria and Tetanus 5 doses toxoid-containing vaccine or 4 doses and Pertussis vaccine 4 doses if the 4th dose was received 3 doses (DTaP/DTP/Tdap/Td)2 at 4 years or older or 3 doses if 7 years or older and the series was started at 1 year or older Tetanus and Diphtheria toxoid-containing vaccine Not applicable 1 dose and Pertussis vaccine adolescent booster (Tdap)3 Polio vaccine (IPV/OPV)4 4 doses 3 doses or 3 doses if the 3rd dose was received at 4 years or older Measles, Mumps and 1 dose 2 doses Rubella vaccine (MMR)5 Hepatitis B vaccine6 3 doses 3 doses or 2 doses of adult hepatitis B vaccine (Recombivax) for children who received the doses at least 4 months apart between the ages of 11 through 15 years Varicella (Chickenpox) 1 dose 2 doses vaccine7 Meningococcal conjugate Grades 2 doses vaccine (MenACWY)8 7, 8, 9, 10 or 1 dose Not applicable and 11: if the dose 1 dose was received at 16 years or older Haemophilus influenzae type b conjugate vaccine 1 to 4 doses Not applicable (Hib)9 Pneumococcal Conjugate 1 to 4 doses Not applicable vaccine (PCV)10 Department of Health 1. -
The Conservative Parliamentary Party the Conservative Parliamentary Party
4 Philip Cowley and Mark Stuart The Conservative parliamentary party The Conservative parliamentary party Philip Cowley and Mark Stuart 1 When the Conservative Party gathered for its first party conference since the 1997 general election, they came to bury the parliamentary party, not to praise it. The preceding five years had seen the party lose its (long-enjoyed) reputation for unity, and the blame for this was laid largely at the feet of the party’s parliamentarians.2 As Peter Riddell noted in The Times, ‘speaker after speaker was loudly cheered whenever they criticised the parliamentary party and its divisions’.3 It was an argument with which both the outgoing and incoming Prime Ministers were in agreement. Just before the 1997 general election, John Major confessed to his biographer that ‘I love my party in the country, but I do not love my parliamentary party’; he was later to claim that ‘divided views – expressed without restraint – in the parliamentary party made our position impossible’.4 And in his first address to the massed ranks of the new parliamentary Labour Party after the election Tony Blair drew attention to the state of the Conservative Party: Look at the Tory Party. Pause. Reflect. Then vow never to emulate. Day after day, when in government they had MPs out there, behaving with the indiscipline and thoughtlessness that was reminiscent of us in the early 80s. Where are they now, those great rebels? His answer was simple: not in Parliament. ‘When the walls came crashing down beneath the tidal wave of change, there was no discrimination between those Tory MPs. -
Vaccinations for Adults with Chronic Liver Disease Or Infection
Vaccinations for Adults with Chronic Liver Disease or Infection This table shows which vaccinations you should have to protect your health if you have chronic hepatitis B or C infection or chronic liver disease (e.g., cirrhosis). Make sure you and your healthcare provider keep your vaccinations up to date. Vaccine Do you need it? Hepatitis A Yes! Your chronic liver disease or infection puts you at risk for serious complications if you get infected with the (HepA) hepatitis A virus. If you’ve never been vaccinated against hepatitis A, you need 2 doses of this vaccine, usually spaced 6–18 months apart. Hepatitis B Yes! If you already have chronic hepatitis B infection, you won’t need hepatitis B vaccine. However, if you have (HepB) hepatitis C or other causes of chronic liver disease, you do need hepatitis B vaccine. The vaccine is given in 2 or 3 doses, depending on the brand. Ask your healthcare provider if you need screening blood tests for hepatitis B. Hib (Haemophilus Maybe. Some adults with certain high-risk conditions, for example, lack of a functioning spleen, need vaccination influenzae type b) with Hib. Talk to your healthcare provider to find out if you need this vaccine. Human Yes! You should get this vaccine if you are age 26 years or younger. Adults age 27 through 45 may also be vacci- papillomavirus nated against HPV after a discussion with their healthcare provider. The vaccine is usually given in 3 doses over a (HPV) 6-month period. Influenza Yes! You need a dose every fall (or winter) for your protection and for the protection of others around you. -
Vaccinations for Preteens and Teens, Age 11-19 Years
Vaccinations for Preteens and Teens, Age 11–19 Years Getting immunized is a lifelong, life-protecting job. Make sure you and your healthcare provider keep your immunizations up to date. Check to be sure you’ve had all the vaccinations you need. Vaccine Do you need it? Chickenpox Yes! If you haven’t been vaccinated and haven’t had chickenpox, you need 2 doses of this vaccine. (varicella; Var) Anybody who was vaccinated with only 1 dose should get a second dose. Hepatitis A Yes! If you haven’t been vaccinated, you need 2 doses of this vaccine. Anybody who was vaccinated (HepA) with only 1 dose should get a second dose at least 6–18 months later. Hepatitis B Yes! This vaccine is recommended for all people age 0–18 years. You need a hepatitis B vaccine series (HepB) if you have not already received it. Haemophilus influ- Maybe. If you haven’t been vaccinated against Hib and have a high-risk condition (such as a non- enzae type b (Hib) functioning spleen), you need this vaccine. Human Yes! All preteens need 2 doses of HPV vaccine at age 11 or 12. Older teens who haven't been vacci- papillomavirus nated will need 2 or 3 doses. This vaccine protects against HPV, a common cause of genital warts and (HPV) several types of cancer, including cervical cancer and cancer of the anus, penis, and throat. Influenza Yes! Everyone age 6 months and older needs annual influenza vaccination every fall or winter and (Flu) for the rest of their lives.